Cargando…

Ordered subset expectation maximisation vs Bayesian penalised likelihood reconstruction algorithm in 18F-PSMA-1007 PET/CT

BACKGROUND: The aim of the study was to compare widely used ordered subset expectation maximisation (OSEM) algorithm with a new Bayesian penalised likelihood (BPL) Q.Clear algorithm in 18F-PSMA-1007 PET/CT. METHODS: We retrospectively assessed 25 18F-PSMA-1007 PET/CT scans with both OSEM and Q.Clear...

Descripción completa

Detalles Bibliográficos
Autores principales:	Witkowska-Patena, Ewa, Budzyńska, Anna, Giżewska, Agnieszka, Dziuk, Mirosław, Walęcka-Mazur, Agata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033087/ https://www.ncbi.nlm.nih.gov/pubmed/31902120 http://dx.doi.org/10.1007/s12149-019-01433-x

Ejemplares similares

68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now?
por: Witkowska-Patena, Ewa, et al.
Publicado: (2017)

18F-FDG Positron Emission Tomography/ Computed Tomography (PET/CT) for Distinguishing Tuberous Sclerosis Complex Lesions from Colon Cancer Metastases
por: Mazurek, Andrzej, et al.
Publicado: (2021)

Optimising quantitative (90)Y PET imaging: an investigation into the effects of scan length and Bayesian penalised likelihood reconstruction
por: Scott, Nathaniel P., et al.
Publicado: (2019)

Novel penalised likelihood reconstruction of PET in the assessment of histologically verified small pulmonary nodules
por: Teoh, Eugene J., et al.
Publicado: (2015)

Rapid Whole-Body FDG PET/MRI in Oncology Patients: Utility of Combining Bayesian Penalised Likelihood PET Reconstruction and Abbreviated MRI
por: Inukai, Junko Inoue, et al.
Publicado: (2023)

Penalising Brownian paths
por: Roynette, Bernard, et al.
Publicado: (2009)

Bayesian penalised likelihood reconstruction (Q.Clear) of (18)F-fluciclovine PET for imaging of recurrent prostate cancer: semi-quantitative and clinical evaluation
por: Teoh, Eugene J, et al.
Publicado: (2018)

Cox models with time‐varying covariates and partly‐interval censoring–A maximum penalised likelihood approach
por: Webb, Annabel, et al.
Publicado: (2022)

Biokinetics and dosimetry of (18)F‐PSMA‐1007 in patients with prostate cancer
por: Hvittfeldt, Erland, et al.
Publicado: (2022)

Skeletal (18)F-PSMA-1007 uptake in prostate cancer patients
por: Janssen, Jorinde, et al.
Publicado: (2023)

Preclinical comparative study of [(18)F]AlF-PSMA-11 and [(18)F]PSMA-1007 in varying PSMA expressing tumors
por: Piron, Sarah, et al.
Publicado: (2022)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

PSMA-Positive Low Malignant Gastrointestinal Stromal Tumor in the Stomach on F-18-PSMA-1007 PET/CT
por: Iversen, Peter, et al.
Publicado: (2022)

PSMA-1007 Uptake in Ganglia of the Sympathetic Trunk and Its Intra-individual Reproducibility
por: Mamlins, E., et al.
Publicado: (2022)

(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
por: Giesel, Frederik L., et al.
Publicado: (2016)

(18)F-PSMA-1007 PET/CT uptake in multiple angiolipomas caused by PSMA expression in capillaries: a case report
por: Wang, Long, et al.
Publicado: (2021)

On the inconsistency of ℓ(1)-penalised sparse precision matrix estimation
por: Heinävaara, Otte, et al.
Publicado: (2016)

Non-prostate uptake on (18)F-PSMA-1007 PET/CT: a case of myeloma
por: Veerasuri, Sowmya, et al.
Publicado: (2020)

Dose-reduced [(18)F]PSMA-1007 PET is feasible for functional imaging of the renal cortex
por: Valind, Kristian, et al.
Publicado: (2021)

[(18)F]F-PSMA-1007 Radiolabelling without an On-Site Cyclotron: A Quality Issue
por: Di Iorio, Valentina, et al.
Publicado: (2021)

(18)F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis
por: Ferrari, Matteo, et al.
Publicado: (2021)

Diagnostic accuracy of [(18)F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer
por: Mingels, Clemens, et al.
Publicado: (2022)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

A hybrid expectation maximisation and MCMC sampling algorithm to implement Bayesian mixture model based genomic prediction and QTL mapping
por: Wang, Tingting, et al.
Publicado: (2016)

A comparison of penalised regression methods for informing the selection of predictive markers
por: Greenwood, Christopher J., et al.
Publicado: (2020)

Diagnostic performance of (18)F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer
por: Rahbar, Kambiz, et al.
Publicado: (2018)

Optimization of [(18)F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer
por: Trägårdh, Elin, et al.
Publicado: (2020)

Frequency and intensity of [(18)F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET
por: Maurer, Alexander, et al.
Publicado: (2022)

[(18)F]PSMA‐1007 renal uptake parameters: Reproducibility and relationship to estimated glomerular filtration rate
por: Valind, Kristian, et al.
Publicado: (2022)

Total Tumor Volume on (18)F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with (225)Ac-PSMA-I&T
por: Unterrainer, Lena M., et al.
Publicado: (2022)

Immature Plasma Cell Myeloma Mimics Metastatic Renal Cell Carcinoma on (18)F-PSMA-1007 PET/CT Due to Endothelial PSMA-Expression
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI
por: Zhang, Yan-Nan, et al.
Publicado: (2022)

18F-FDG PET/CT assessment of histopathologically confirmed mediastinal lymph nodes in non-small cell lung cancer using a penalised likelihood reconstruction
por: Teoh, Eugene J., et al.
Publicado: (2016)

The value of (18)F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer
por: Hong, Jun-jie, et al.
Publicado: (2020)

Automated [(18)F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination
por: Naka, Sadahiro, et al.
Publicado: (2020)

Diagnostic Role of (18)F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review
por: Awenat, Salam, et al.
Publicado: (2021)

Risk of metastatic disease using [(18)F]PSMA-1007 PET/CT for primary prostate cancer staging
por: Chikatamarla, Venkata Avinash, et al.
Publicado: (2021)

An exploratory study of unexplained concentration of (18)F-PSMA-1007 in the bladder for prostate cancer PET/CT imaging
por: Dang, Jun, et al.
Publicado: (2023)

Intraindividual comparison of [(68) Ga]-Ga-PSMA-11 and [(18)F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis
por: Hoberück, Sebastian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cs889n13u4oevjs8fn2mgrmrc8